

PATIENT		SAMPLE		PROVIDER	
First Name	Jane	Sample Type	Blood	Provider	John Smith
Last Name	Doe	Date Collected	09/25/2022	Clinic Address	1035 O'Brien Drive Menlo Park, CA 94025
DOB	01/01/2000	Date Received	09/26/2022	Phone Number	650-460-2551
Ethnicity	Northern European/White	Accession ID	1234567X0000	Fax Number	883-915-0146
Gender	Female	Requisition ID	1234567X0000-1		
Gestational Age	10w4d	Date Reported	10/06/2022		
Medical Record #	N/A				

UNITY™ Carrier Screen with Reflex sgNIPT

POSITIVE CARRIER

HIGH RISK FETUS

CONDITIONS SCREENED	MATERNAL CARRIER STATUS	FETAL RISK BY sgNIPT
Alpha-Thalassemia (HBA1, HBA2)	Negative	
Sickle Cell Disease / Beta-Thalassemia / Hemoglobinopathies (HBB)	POSITIVE Sickle cell: c.20A>T (p.Glu7Val)	HIGH RISK <i>See Results Below</i>
Cystic Fibrosis (CFTR)	Negative	
Spinal Muscular Atrophy (SMN1)	Negative 2 SMN1 copies, SNP not present	

sgNIPT RESULT DETAILS


CONDITIONS SCREENED	FETAL RISK	Risk Before sgNIPT	Risk After sgNIPT	Fetal Fraction
Sickle Cell Disease / Beta-Thalassemia / Hemoglobinopathies	HIGH	1 in 32 - 1 in 1,492	9 in 10	9.9%
		Fetal Risk Before sgNIPT is dependent on paternal ethnicity and assumes paternal carrier status is unknown. See disease carrier frequencies based on ethnicity on the last page of the report.		


Recommended Follow-Up *next page*


The ACOG Committee on Genetics (co486 and co691) recommends cystic fibrosis, hemoglobinopathy, and spinal muscular atrophy carrier screening for all patients who are planning a pregnancy or seeking prenatal care. UNITY™ carrier screening evaluates for cystic fibrosis (CFTR), hemoglobinopathies (HBB, HBA1 and HBA2), and spinal muscular atrophy (SMN1). Reflex sgNIPT is performed to evaluate fetal risk when a pregnant patient is identified as a carrier for these conditions.

Patient Name Jane Doe	DOB 01/01/2000	Gestational Age 10w4d	Medical Record # N/A
------------------------------	-----------------------	------------------------------	-----------------------------

RECOMMENDED FOLLOW-UP

 **PRENATAL DIAGNOSIS** via chorionic villus sampling or amniocentesis is **RECOMMENDED** for sickle cell disease / beta-thalassemia / hemoglobinopathies.

 **GENETIC COUNSELING** is **recommended** to review the implications of this result.
The patient may contact BillionToOne at (650) 460-2551 to schedule an appointment for a complimentary telephone genetic consultation to review these results. A genetic counselor can also be found at www.nsgc.org.

 **CARRIER SCREENING** for sickle cell disease / beta-thalassemia / hemoglobinopathies for the patient's reproductive partner is **recommended** prior to a future pregnancy.

Interpretation *next page* >

Patient Name Jane Doe	DOB 01/01/2000	Gestational Age 10w4d	Medical Record # N/A
------------------------------	-----------------------	------------------------------	-----------------------------

INTERPRETATION

UNITY™ Carrier Screen

This patient has the c.20A>T (p.Glu7Val) (Sickle cell) pathogenic variant in the *HBB* (NM_000518.5) gene and is a CARRIER for sickle cell disease.

If this patient's reproductive partner is a carrier for sickle cell disease / beta-thalassemia / hemoglobinopathies, there is a 25% risk for an affected child with each pregnancy. Carrier screening for sickle cell disease / beta-thalassemia / hemoglobinopathies for the patient's reproductive partner is recommended prior to a future pregnancy to clarify the risks for an affected child.

This patient's first-degree relatives each have a 50% chance to be a carrier for sickle cell disease as well. We recommend these results be shared with blood relatives, especially those of reproductive age.

UNITY™ sgNIPT for Sickle Cell Disease / Beta-Thalassemia / Hemoglobinopathies

The fetus is HIGH RISK to be affected with sickle cell disease. The estimated fetal fraction was 9.9%.

sgNIPT was performed to evaluate for fetal *HBB* variants and concluded the fetus is high risk to be homozygous for the c.20A>T (p.Glu7Val) pathogenic variant in the *HBB* gene. Therefore, the fetus is at HIGH RISK to be affected with sickle cell disease.

This sgNIPT result is valid only for a singleton pregnancy achieved without egg donation or gestational carrier.

Prenatal diagnosis via chorionic villus sampling or amniocentesis is recommended. UNITY™ sgNIPT is not diagnostic. No irreversible decisions regarding the pregnancy should be made without confirmatory invasive prenatal testing. Genetic testing can also be performed postnatally.

Genetic counseling is recommended for this patient to review the implications of this result. The patient may contact BillionToOne at (650) 460-2551 to schedule an appointment for a complimentary telephone genetic consultation to review these results. A genetic counselor can also be found at www.nsgc.org.

Patient Name Jane Doe

DOB 01/01/2000

Gestational Age 10w4d

Medical Record # N/A

INTERPRETATION

UNITY™ Carrier Screen

No other reportable gene variants were found.

Alpha-Thalassemia <i>HBA1</i> (NM_000558.5), <i>HBA2</i> (NM_000517.6)	Negative
Cystic Fibrosis <i>CFTR</i> (NM_000492.3)	Negative
Spinal Muscular Atrophy <i>SMN1</i> (NM_000344.3) <ul style="list-style-type: none"> <i>SMN1</i> Copy Number SMA Region Informative SNP (rs143838139) 	Negative <ul style="list-style-type: none"> 2 copies (most common) Not Present (most common haplotype)

Carrier frequencies both before and after screening vary by ethnicity and assume no personal or family history of the condition. See Pre- and Post-Test Carrier Frequencies tables on the last page of the report.

Comprehensive genetic counseling is recommended for a patient with a family history of a genetic disorder so that carrier risks can be accurately discussed, as well as potential reproductive risks and additional testing options that may be available.

Carrier screening does not evaluate for all genetic conditions. In addition, carrier screening is not able to identify all possible variants in the genes analyzed. As a result, a negative result significantly reduces the probability of being a carrier; it does not eliminate the risk.

METHODS AND LIMITATIONS

UNITY™ Carrier Screen

DNA was extracted and purified from leukocyte enriched peripheral blood. The resulting DNA was subjected to a Custom Amplicon Panel PCR that utilized Spikein DNA technology to detect both small nucleotide variants and large copy number changes. The DNA was sequenced by synthesis on an Illumina NextSeq. Results were aligned and examined on a custom bioinformatics pipeline and compared to the published human genome build GRCh37/hg19 reference sequence. NGS performance of small nucleotide variants (SNV) was confirmed via Sanger sequencing for any variants with sequencing coverage less than 100x and for rare variants in genes that have not yet been confirmed by Sanger sequencing 10 times. Large copy number variants were confirmed using digital Multiplex Ligation Probe Amplification (digitalMLPA). Pathogenic and likely pathogenic variants were reported.

Test limitations: A negative result significantly reduces but does not eliminate the chance of being a carrier. Additional carrier screening may be indicated for individuals of Ashkenazi Jewish, French Canadian, or Cajun descent, as these patients are at higher risk of diseases that we do not test in our panel.

Test sensitivity and mutation spectrum: UNITY™ is designed to maximize detection of pathogenic alleles for cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies (alpha-thalassemia, beta-thalassemia, and sickle cell disease). We sequence all exons, exon-intron junctions and select intronic regions of *CFTR*, *HBA1*, *HBA2*, and *HBB*. Copy number analysis is performed on *CFTR*, *SMN1*, *HBA1*, *HBA2*, and *HBB*. This includes all *CFTR* variants recommended by the American College of Medical Genetics (ACMG), all common *HBB* variants including HbS, HbC, HbE, IVS1-1, and 41/42-TTCT, the *HBA2* Constant Spring variant and the *SMN1* silent carrier linked SNP g.27134T>G (rs143838139) when two copies of *SMN1* are present. The alpha-thalassemia carrier screen also reports single and double gene deletions including alpha3.7, alpha4.2, SEA, MED-1, SA, 20.5, BRIT, FIL or THAI.

UNITY™ sgNIPT

Cell-free DNA (cfDNA) was isolated from 2-4mL of plasma from whole blood collected in a Streck cell-free DNA tube. A paternal inheritance sgNIPT was performed as a multiplex PCR on common single nucleotide variants (SNVs) to measure the fraction of cell-free DNA of fetal origin. The paternal inheritance sgNIPT also contains amplicons for *CFTR* and *HBB* for paternal exclusion analysis of pathogenic alleles. Recessive inheritance of certain common maternal variants, i.e., fetal inheritance of the same pathogenic allele from both parents, was determined by a separate PCR on cfDNA to perform Relative Mutation Dosage analysis using BillionToOne's QCT molecular counting technology as available. When multiple blood tubes are analyzed for sgNIPT (e.g., for redraws), we report the combined reported fetal fraction by taking the weighted average of fetal fractions across different tubes based on the total number of molecules identified via QCTs. Due to the tube-to-tube assay variability, the reported fetal fraction for the same patient can differ between single-gene NIPT and aneuploidy NIPT.

Test Limitations: Single gene NIPT may not be reported when the amount of cell-free DNA in the blood sample is too low. sgNIPT is not performed on genes that are not covered on the UNITY™ Carrier Screen panel (e.g., Tay-Sachs, Canavan, familial dysautonomia). The sgNIPT result is valid only for a singleton pregnancy achieved without egg donation or gestational carrier. UNITY™ is designed and optimized as a general population screening tool, and additional information regarding maternal and paternal mutations should be supplied to the laboratory for appropriate risk adjustment in cases where the test is being used for high-risk couples where paternal carrier status is known. Relative Mutation Dosage analysis for the identification of homozygosity is not available for all variants. Therefore, in rare cases (less than 1% of affected pregnancies), sgNIPT may not detect a homozygous affected fetus. While this limitation is accounted for in the post-test sgNIPT risk for the general population, the reported sgNIPT post-test risk may not adequately represent the residual risk for consanguineous couples.

Test sensitivity and mutation spectrum: Next generation sequencing of critical exons and introns in *HBB* and *CFTR* was performed. The *HBB* sgNIPT detects >99% of pathogenic alleles and the cystic fibrosis sgNIPT detects >94% of pathogenic alleles. When performed on double deletion in cis ($--/aa$) carriers, the *HBA* sgNIPT detects or excludes paternal inheritance of the double gene deletion in cis (SEA, SA, BRIT, FIL or THAI) through a combination of detection of common paternal SNVs in the *HBA1-HBA2* locus and breakpoint PCR. Additionally, *HBA* sgNIPT detects paternal inheritance of the Hb Constant Spring allele. When performed on Alpha Thalassemia single gene deletion ($-a/aa$) carriers, double gene deletion carriers in trans ($-a/-a$) or Hb Constant Spring carriers ($acsa/aa$), the *HBA* sgNIPT detects paternal inheritance of the SEA deletion using breakpoint PCR. When performed on Alpha Thalassemia non-deletion variant ($anda/aa$) carriers with a variant other than Hb Constant Spring the *HBA* sgNIPT detects paternal inheritance of the SEA deletion via breakpoint PCR and detects paternal inheritance of the Hb Constant Spring allele. The *SMA* sgNIPT detects inheritance of *SMN1* copy number.

Carrier screen genotypes excluded from sgNIPT analysis: *SMN1* sgNIPT is not performed for two copy, SNP positive individuals.

This carrier screen and NIPT was developed and its performance characteristics determined by the BillionToOne laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. The BillionToOne laboratory is regulated under CLIA. This test is used for clinical purposes. It should not be regarded as investigational or for research.

BillionToOne Laboratory
1035 O'Brien Drive
Menlo Park, CA 94025

Laboratory Director Joseph Michael Anderson, MD
CLIA ID 05D2167800
CLF 00353741

Phone (650) 460-2551
Fax (833) 915-0146
Email support@unityscreen.com



Joseph Michael Anderson, MD
Laboratory Director
California License: A 98379

UNITY™ CARRIER SCREEN: CARRIER FREQUENCIES

Disease	Gene	Ethnicity	Carrier Frequency Before Testing	Detection Rate	Carrier Risk After Negative Testing
Alpha-Thalassemia Alpha thalassemia silent carrier includes the single allele deletion and trans double allele deletion. Double deletion includes cis double deletion only. CS means Constant Spring mutation	<i>HBA1, HBA2</i>	African American	aa/a-: 1 in 3 aa/--: 1 in 5,000 aa/aa ^{CS} : 1 in 10,000	>95%	aa/a-: 1 in 60 aa/--: 1 in 100,000 aa/aa ^{CS} : 1 in 200,000
		Asian	aa/a-: 1 in 16 aa/--: 1 in 93 aa/aa ^{CS} : 1 in 93	>95%	aa/a-: 1 in 320 aa/--: 1 in 1860 aa/aa ^{CS} : 1 in 1860
		Northern European	aa/a-: 1 in 44 aa/--: 1 in 3807 aa/aa ^{CS} : 1 in 10,000	>95%	aa/a-: 1 in 880 aa/--: 1 in 76,140 aa/aa ^{CS} : 1 in 200,000
		General Population	aa/a-: 1 in 16 aa/--: 1 in 570 aa/aa ^{CS} : 1 in 10,000	>95%	aa/a-: 1 in 320 aa/--: 1 in 11,400 aa/aa ^{CS} : 1 in 200,000
Sickle Cell Disease, Beta-Thalassemia, Hemoglobiopathies	<i>HBB</i>	African American	1 in 8	>99%	<1 in 800
		Ashkenazi Jewish	1 in 49	>99%	<1 in 4900
		Asian	1 in 54	>99%	<1 in 5400
		Northern European	1 in 373	>99%	<1 in 37,300
		Hispanic	1 in 17	>99%	<1 in 1700
		Mediterranean	1 in 28	>99%	<1 in 2800
		General Population	1 in 49	>99%	<1 in 4900
Cystic Fibrosis	<i>CFTR</i>	African American	1 in 61	>99%	<1 in 6100
		Ashkenazi Jewish	1 in 24	>99%	<1 in 2400
		Asian	1 in 94	>99%	<1 in 9400
		Northern European	1 in 25	>99%	<1 in 2500
		Hispanic	1 in 58	>99%	<1 in 5800
		General Population	1 in 45	>99%	<1 in 4500
Spinal Muscular Atrophy	<i>SMN1</i>	African American	1 in 72	>90.3%	<1 in 375 (2 copies, SNP absent) <1 in 4200 (3+ copies)
		Ashkenazi Jewish	1 in 67	>92.8%	<1 in 900 (2 copies, SNP absent) <1 in 5400 (3+ copies)
		Asian	1 in 59	>93.6%	<1 in 900 (2 copies, SNP absent) <1 in 5600 (3+ copies)
		Northern European	1 in 47	>95%	<1 in 900 (2 copies, SNP absent) <1 in 5600 (3+ copies)
		Hispanic	1 in 68	>92.6%	<1 in 900 (2 copies, SNP absent) <1 in 5400 (3+ copies)
		General Population	1 in 54	>91.2%	<1 in 525 (2 copies, SNP absent) <1 in 5400 (3+ copies)

SICKLE CELL DISEASE CARRIER – HIGH RISK FETUS

SICKLE CELL DISEASE

Sickle cell disease is an inherited condition that belongs to a group of conditions called beta-hemoglobinopathies that affect the blood's ability to transport oxygen to organs throughout the body. Sickle cell disease causes red blood cells to form in a sickled or halfmoon shape. This shape causes red blood cells to harden and get stuck in blood vessels. Since red blood cells are responsible for transporting oxygen, this results in decreased oxygen throughout the body. Symptoms begin in early childhood and include fatigue, shortness of breath, severe pain, damage to organs, infection, and stroke. The severity of symptoms varies from person to person. Lifelong treatment is required to improve quality of life and reduce the chance of fatal complications.

Individuals with sickle cell disease are treated with pain medication, hydration, and blood transfusions. Stem cell transplant may be a curative option for some people.

WHAT CAUSES SICKLE CELL DISEASE?

Everyone has two copies of the *HBB* gene. Sickle cell disease and other beta-hemoglobinopathies are caused when a child inherits two non-working copies of the *HBB* gene, one from their mother and one from their father. If someone has one non-working copy of the *HBB* gene, they are called a carrier (sickle cell trait). When both parents are carriers of sickle cell disease or other beta-hemoglobinopathy, there is a 25% (1 in 4) chance to have an affected child with each pregnancy. UNITY™ uses advanced technology to determine if you are a carrier and if your current pregnancy is at risk.

YOUR CARRIER STATUS: CARRIER OF SICKLE CELL DISEASE

You were identified to be a carrier of sickle cell disease (also known as sickle cell trait). Carriers of sickle cell disease are typically healthy and do not have symptoms unless they are exposed to extreme conditions. When carriers of sickle cell disease are exposed to very high altitudes, dehydration, or extreme physical exertion they may experience symptoms similar to individuals who have sickle cell disease. Some rare forms of kidney cancer are more common in individuals with sickle cell trait.

Carrier screening for sickle cell disease/beta-thalassemia for the father of your children is recommended prior to a future pregnancy to clarify the risk to have an affected child. Your first-degree relatives (e.g., brothers, sisters, children, and parents) have a 50% chance to be a carrier of sickle cell disease. More distant relatives also have a chance to be a carrier. We recommend that you share these results with blood relatives, especially those of reproductive age.

YOUR BABY'S RISK: HIGH CHANCE TO BE AFFECTED WITH SICKLE CELL DISEASE/BETA-HEMOGLOBINOPATHY

The testing performed by UNITY™ shows your baby's chance of being affected with sickle cell disease or other beta-hemoglobinopathy is **significantly increased**. Please reference your report to review personalized risk figures as well as the specific type of beta-hemoglobinopathy your baby is at high risk for. **No irreversible pregnancy decisions, such as pregnancy termination, should be considered based on UNITY™ results alone.**

Follow-up testing and genetic counseling is strongly recommended. You may contact BillionToOne at (650) 460-2551 to schedule an appointment for a complimentary telephone genetic consultation to review these results. A local genetic counselor can also be found at www.nsgc.org.

SICKLE CELL DISEASE CARRIER – HIGH RISK FETUS

CONFIRMATORY TESTING

Although UNITY™ is a highly accurate screening test, diagnostic testing is strongly recommended to determine whether your baby is affected with sickle cell disease/beta-hemoglobinopathy. UNITY™ uses an advanced technology to determine whether your baby's risk to have sickle cell disease/beta-hemoglobinopathy is high or low. Confirmatory genetic testing during pregnancy or after birth can determine whether or not your baby is actually affected.

Before Birth

Testing for sickle cell disease/beta-hemoglobinopathy during pregnancy can be performed by obtaining a sample of placenta (chorionic villus sampling or CVS) or fluid around your baby (amniocentesis) which both contain DNA that is representative of your baby. A CVS is ideally performed between 10 to 13 weeks pregnancy while an amniocentesis is performed between 15 to 24 weeks pregnancy. Both procedures are safe, but have a small risk for pregnancy complications, including miscarriage.

After Birth

Testing for your baby can be performed after birth through a blood test. All babies born in a hospital in the United States are automatically screened for sickle cell disease/beta-hemoglobinopathy. The majority of babies with sickle cell disease/beta-hemoglobinopathy will be diagnosed through this screening process. In rare cases, a diagnosis may be missed or incorrectly diagnosed.

RESOURCES

American Society of Hematology: <https://www.hematology.org/Patients/Anemia/Sickle-Cell.aspx/>

American Sickle Cell Anemia Association: <http://www.ascaa.org/>

Sickle Cell Information Center: <http://scinfo.org/>